Adaptive Study Design OK For Single-Arm Trials, FDA Says
Executive Summary
A newly finalized guidance document offers the US agency’s take on how and when clinical trials can be modified midstream. It includes some revisions from a draft version, including more attention paid the possibility of adaptive single-arm trials.